Cancer Cell Metabolism

  • Akash Patnaik
  • Jason W. Locasale
  • Lewis C. CantleyEmail author
Part of the Cancer Drug Discovery and Development book series (CDD&D)


Human cancers result from multiple molecular aberrations, which act in concert with both the tumor microenvironment and metabolic macroenvironment to produce the malignant phenotype. Cancer cells exhibit fundamental differences in both anabolic and catabolic metabolism relative to their normal counterparts. Understanding cancer, the metabolic rewiring of cells that drives transformation may provide novel, selective therapeutic opportunities. This altered metabolism of cancer cells appears to be multifaceted involving the energy sensing machinery, as well as fatty acid, amino acid, and glycolytic metabolism. In this chapter, we describe several important features of the differential metabolism in cancer cells that may contribute to the development of a selective growth, proliferation, and survival advantage. We conclude with a summary of pharmaceutical interventions already in clinical use or currently under investigation that target this altered metabolism in human cancers.


Prostate Cancer KRAS Mutation Aerobic Glycolysis Folate Antagonist HCT116 Colon Cancer Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Calle, E.E., et al., Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. New England Journal of Medicine, 2003. 348(17): p. 1625–1638.PubMedCrossRefGoogle Scholar
  2. Michalakis, K., et al., Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: A case control study. Cancer Epidemiology Biomarkers & Prevention, 2007. 16(2): p. 308–313.CrossRefGoogle Scholar
  3. Zakikhani, M., et al., The Effects of Adiponectin and Metformin on Prostate and Colon Neoplasia Involve Activation of AMP-Activated Protein Kinase. Cancer Prevention Research, 2008. 1(5): p. 369–375.PubMedCrossRefGoogle Scholar
  4. Hardie, D.G., AMPK: a key regulator of energy balance in the single cell and the whole organism. International Journal of Obesity, 2008. 32: p. S7–S12.PubMedCrossRefGoogle Scholar
  5. Woods, A., et al., LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol, 2003. 13(22): p. 2004–8.PubMedCrossRefGoogle Scholar
  6. Jenne, D.E., et al., Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nature Genetics, 1998. 18(1): p. 38–44.PubMedCrossRefGoogle Scholar
  7. Orlova, K.A., et al., STRAD alpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice. Journal of Clinical Investigation, 2010. 120(5): p. 1591–1602.PubMedCrossRefGoogle Scholar
  8. Pearson, H.B., et al., Lkb1 deficiency causes prostate neoplasia in the mouse. Cancer Research, 2008. 68(7): p. 2223–2232.PubMedCrossRefGoogle Scholar
  9. Shackelford, D.B. and R.J. Shaw, The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nature Reviews Cancer, 2009. 9(8): p. 563–575.PubMedCrossRefGoogle Scholar
  10. Luo, Z.J., et al., AMPK, the metabolic syndrome and cancer. Trends in Pharmacological Sciences, 2005. 26(2): p. 69–76.PubMedCrossRefGoogle Scholar
  11. Ruderman, N. and M. Prentki, AMP kinase and malonyl-CoA: Targets for therapy of the metabolic syndrome. Nature Reviews Drug Discovery, 2004. 3(4): p. 340–351.PubMedCrossRefGoogle Scholar
  12. Horikoshi, M., et al., A polymorphism in the AMPK alpha 2 subunit gene is associated with insulin resistance and type 2 diabetes in the Japanese population. Diabetes, 2006. 55(4): p. 919–923.PubMedCrossRefGoogle Scholar
  13. Viollet, B., et al., Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. Biochemical Society Transactions, 2003. 31: p. 216–219.PubMedCrossRefGoogle Scholar
  14. Matsui, H., et al., Genomewide linkage analysis of familial prostate cancer in the Japanese population. Journal of Human Genetics, 2004. 49(1): p. 9–15.PubMedCrossRefGoogle Scholar
  15. Takane, H., et al., Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics, 2008. 9(4): p. 415–422.PubMedCrossRefGoogle Scholar
  16. Algire, C., et al., Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocrine-Related Cancer, 2008. 15(3): p. 833–839.PubMedCrossRefGoogle Scholar
  17. Wakil, S.J., FATTY-ACID SYNTHASE, A PROFICIENT MULTIFUNCTIONAL ENZYME. Biochemistry, 1989. 28(11): p. 4523–4530.PubMedCrossRefGoogle Scholar
  18. Menendez, J.A. and R. Lupu, Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature Reviews Cancer, 2007. 7(10): p. 763–777.PubMedCrossRefGoogle Scholar
  19. Pizer, E.S., et al., Fatty acid synthase (FAS): A target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells. Cancer Research, 1996. 56(4): p. 745–751.PubMedGoogle Scholar
  20. Wang, W.Q., et al., Increased fatty acid synthase as a potential therapeutic target in multiple myeloma. Journal of Zhejiang University-Science B, 2008. 9(6): p. 441–447.PubMedCrossRefGoogle Scholar
  21. Kuhajda, F.P., Fatty acid synthase and cancer: New application of an old pathway. Cancer Research, 2006. 66(12): p. 5977–5980.PubMedCrossRefGoogle Scholar
  22. Menendez, J.A., et al., Pharmacological inhibition of fatty acid synthase (FAS): A novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. Molecular Carcinogenesis, 2004. 41(3): p. 164–178.PubMedCrossRefGoogle Scholar
  23. Coleman, D.T., R. Bigelow, and J.A. Cardelli, Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation. Molecular Cancer Therapeutics, 2009. 8(1): p. 214–224.PubMedCrossRefGoogle Scholar
  24. Engelman, J.A., J. Luo, and L.C. Cantley, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet, 2006. 7(8): p. 606–19.PubMedCrossRefGoogle Scholar
  25. Swinnen, J.V., et al., Selective activation of the fatty acid synthesis pathway in human prostate cancer. International Journal of Cancer, 2000. 88(2): p. 176–179.CrossRefGoogle Scholar
  26. Rossi, S., et al., Fatty acid synthase molecular signatures expression defines distinct in prostate cancer. Molecular Cancer Research, 2003. 1(10): p. 707–715.PubMedGoogle Scholar
  27. Ettinger, S.L., et al., Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Research, 2004. 64(6): p. 2212–2221.PubMedCrossRefGoogle Scholar
  28. Sansal, I. and W.R. Sellers, The biology and clinical relevance of the PTEN tumor suppressor pathway. Journal of Clinical Oncology, 2004. 22(14): p. 2954–2963.PubMedCrossRefGoogle Scholar
  29. Nomura, D.K., et al., Monoacylglycerol Lipase Regulates a Fatty Acid Network that Promotes Cancer Pathogenesis. Cell, 2010. 140(1): p. 49–61.PubMedCrossRefGoogle Scholar
  30. Sreekumar, A., et al., Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 2009. 457(7231): p. 910–914.PubMedCrossRefGoogle Scholar
  31. Warburg, O., On the origin of cancer cells. Science, 1956. 123(3191): p. 309–14.PubMedCrossRefGoogle Scholar
  32. Warburg, O., K. Posener, and E. Negelein, Ueber den Stoffwechsel der Tumoren Biochemische Zeitschrift, 1924. 152: p. 319–344.Google Scholar
  33. Deberardinis, R.J., et al., The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab, 2008. 7(1): p. 11–20.PubMedCrossRefGoogle Scholar
  34. VanderHeiden, M.G., L.C. Cantley, and C.B. Thompson, Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 2009. 324(5930): p. 1029–33.PubMedCrossRefGoogle Scholar
  35. Locasale, J.W., L.C. Cantley, and M.G. Vander Heiden, Cancer’s insatiable appetite. Nature Biotechnology, 2009. 27(10): p. 916–917.PubMedCrossRefGoogle Scholar
  36. Yun, J., et al., Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells. Science, 2009. 18; 325(5947): p. 1555–9.Google Scholar
  37. Manning, B.D. and L.C. Cantley, AKT/PKB signaling: Navigating downstream. Cell, 2007. 129(7): p. 1261–1274.PubMedCrossRefGoogle Scholar
  38. Bensaad, K., et al., TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell, 2006. 126(1): p. 107–20.PubMedCrossRefGoogle Scholar
  39. Laplante, M. and D.M. Sabatini, mTORC1 activates SREBP-1c and uncouples lipogenesis from gluconeogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2010. 107(8): p. 3281–3282.PubMedCrossRefGoogle Scholar
  40. Kaelin, W.G., Jr. and P.J. Ratcliffe, Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell, 2008. 30(4): p. 393–402.Google Scholar
  41. Meyer, N. and L.Z. Penn, MYC - TIMELINE Reflecting on 25 years with MYC. Nature Reviews Cancer, 2008. 8(12): p. 976–990.PubMedCrossRefGoogle Scholar
  42. Beroukhim, R., et al., The landscape of somatic copy-number alteration across human cancers. Nature, 2010. 463(7283): p. 899–905.PubMedCrossRefGoogle Scholar
  43. Wise, D.R., et al., Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A, 2008. 105(48): p. 18782–7.PubMedCrossRefGoogle Scholar
  44. DeBerardinis, R.J., et al., Brick by brick: metabolism and tumor cell growth. Current Opinion in Genetics & Development, 2008. 18(1): p. 54–61.CrossRefGoogle Scholar
  45. David, C.J., et al., HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature, 2010. 463(7279): p. 364-U114.PubMedCrossRefGoogle Scholar
  46. Dang, C.V., et al., The interplay between MYC and HIF in cancer. Nat Rev Cancer, 2008. 8(1): p. 51–6.PubMedCrossRefGoogle Scholar
  47. Vousden, K.H. and K.M. Ryan, p53 and metabolism. Nature Reviews Cancer, 2009. 9(10): p. 691–700.PubMedCrossRefGoogle Scholar
  48. Hu, W.W., et al., Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proceedings of the National Academy of Sciences of the United States of America, 2010. 107(16): p. 7455–7460.PubMedCrossRefGoogle Scholar
  49. Suzuki, S., et al., Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proceedings of the National Academy of Sciences of the United States of America, 2010. 107(16): p. 7461–7466.PubMedCrossRefGoogle Scholar
  50. Tennant, D.A., R.V. Duran, and E. Gottlieb, Targeting metabolic transformation for cancer therapy. Nature Reviews Cancer, 2010. 10(4): p. 267–277.PubMedCrossRefGoogle Scholar
  51. Farber, S., et al., TEMPORARY REMISSIONS IN ACUTE LEUKEMIA IN CHILDREN PRODUCED BY FOLIC ACID ANTAGONIST, 4-AMINOPTEROYL-GLUTAMIC ACID (AMINOPTERIN). New England Journal of Medicine, 1948. 238(23): p. 787–793.PubMedCrossRefGoogle Scholar
  52. Jolivet, J., et al., THE PHARMACOLOGY AND CLINICAL USE OF METHOTREXATE. New England Journal of Medicine, 1983. 309(18): p. 1094–1104.PubMedCrossRefGoogle Scholar
  53. Chabner, B.A. and T.G. Roberts, Timeline - Chemotherapy and the war on cancer. Nature Reviews Cancer, 2005. 5(1): p. 65–72.PubMedCrossRefGoogle Scholar
  54. Ben Sahra, I., et al., The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 2008. 27(25): p. 3576–3586.PubMedCrossRefGoogle Scholar
  55. Xiao, B., et al., Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature, 2007. 449(7161): p. 496-U14.PubMedCrossRefGoogle Scholar
  56. Cool, B., et al., Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metabolism, 2006. 3(6): p. 403–416.PubMedCrossRefGoogle Scholar
  57. Huang, X., et al., Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J, 2008. 412(2): p. 211–21.PubMedCrossRefGoogle Scholar
  58. Pang, T., et al., Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. Journal of Biological Chemistry, 2008. 283(23): p. 16051–16060.PubMedCrossRefGoogle Scholar
  59. Currie, C.J., C.D. Poole, and E.A.M. Gale, The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia, 2009. 52(9): p. 1766–1777.PubMedCrossRefGoogle Scholar
  60. Wright, J.L. and J.L. Stanford, Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes & Control, 2009. 20(9): p. 1617–1622.CrossRefGoogle Scholar
  61. Jiralerspong, S., et al., Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol, 2009. 27(20): p. 3297–302.PubMedCrossRefGoogle Scholar
  62. Dowling, R.J.O., et al., Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Research, 2007. 67(22): p. 10804–10812.PubMedCrossRefGoogle Scholar
  63. Shaw, R.J., et al., The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A, 2004. 101(10): p. 3329–35.PubMedCrossRefGoogle Scholar
  64. Hirsch, H.A., et al., Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission (vol 69, pg 7507, 2009). Cancer Research, 2009. 69(22): p. 8832–8833.Google Scholar
  65. Kim, Y.D., et al., Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes, 2008. 57(2): p. 306–314.PubMedCrossRefGoogle Scholar
  66. Goodwin, P.J., J.A. Ligibel, and V. Stambolic, Metformin in Breast Cancer: Time for Action. Journal of Clinical Oncology, 2009. 27(20): p. 3271–3273.PubMedCrossRefGoogle Scholar
  67. Hadad, S.M., et al., Histological evaluation of AMPK signalling in primary breast cancer. Bmc Cancer, 2009. 9.Google Scholar
  68. Migita, T., et al., Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer. Journal of the National Cancer Institute, 2009. 101(7): p. 519–532.PubMedCrossRefGoogle Scholar
  69. Flavin, R., et al., Fatty acid synthase as a potential therapeutic target in cancer. Future Oncology, 2010. 6(4): p. 551–562.PubMedCrossRefGoogle Scholar
  70. Murtola, T.J., Men Presenting for Radical Prostatectomy on Preoperative Statin Therapy Have Reduced Serum Prostate Specific Antigen EDITORIAL COMMENT. Journal of Urology, 2010. 183(1): p. 124–124.PubMedCrossRefGoogle Scholar
  71. Beckers, A., et al., Chemical inhibition of Acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Research, 2007. 67(17): p. 8180–8187.PubMedCrossRefGoogle Scholar
  72. Picchio, M., et al., PET-CT for treatment planning in prostate cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2009. 53(2): p. 245–268.PubMedGoogle Scholar
  73. Christofk, H.R., et al., The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature, 2008. 452(7184): p. 230–3.PubMedCrossRefGoogle Scholar
  74. Boxer, M.B., et al., Evaluation of Substituted N,N’-Diarylsulfonamides as Activators of the Tumor Cell Specific M2 Isoform of Pyruvate Kinase. Journal of Medicinal Chemistry, 2010. 53(3): p. 1048–1055.PubMedCrossRefGoogle Scholar
  75. Stock, C.C., et al., AZASERINE, A NEW TUMOUR-INHIBITORY SUBSTANCE - STUDIES WITH CROCKER MOUSE SARCOMA-180. Nature, 1954. 173(4393): p. 71–72.PubMedCrossRefGoogle Scholar
  76. da Silva, A.P.P., et al., Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochemical Journal, 2009. 417: p. 717–726.CrossRefGoogle Scholar
  77. Michelakis, E.D., et al., Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med, 2010. 2(31): p. 31ra34.PubMedCrossRefGoogle Scholar
  78. Fantin, V.R., J. St-Pierre, and P. Leder, Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 2006. 9(6): p. 425–34.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Akash Patnaik
    • 1
    • 2
    • 3
  • Jason W. Locasale
    • 2
    • 3
  • Lewis C. Cantley
    • 2
    • 3
    Email author
  1. 1.Division of Hematology/Oncology, Department of MedicineBeth Israel Deaconess Medical CenterBostonUSA
  2. 2.Division of Signal Transduction, Department of MedicineBeth Israel Deaconess Medical CenterBostonUSA
  3. 3.Department of Systems BiologyHarvard Medical SchoolBostonUSA

Personalised recommendations